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Background
Head and neck squamous cell carcinoma (HNSCC) is the
6th leading cause of cancer by incidence worldwide with
approximately 600,000 new cases per year. While some
patients respond to immunotherapy, the majority of
patients fail to experience benefit.
Methods
Our group formed a multidisciplinary group to study the
immunobiology of HNSCC and to develop strategies to
effectively treat this disease. Over the past 3 years we have
collected and processed more than 192 HNSCC speci-
mens. Starting in June of 2013 we began to set up cultures
of tumor-infiltrating lymphocytes (TIL) from specimens
with sufficient numbers of cells isolated by triple enzyme
digestion. Between June 13, 2013 and May 14, 2015 we
processed 120 specimens. Fourty-one were processed but
were not set-up for TIL culture. Sixteen were determined
to be grossly contaminated within 18-24 hours and
excluded from further analysis. Sixty-three TIL cultures
were initiated and 33 generated TIL (52%).
Results
At this time, 22 of these have been tested for autologous
tumor reactivity by IFN-g release. Of these 22 TIL, only 2
(9%) did not exhibit autologous tumor-specific secretion
of IFN-g. An additional 3 TIL cultures exhibited low levels
of IFN-g secretion. We interpret these results to suggest
that at least half of the patients in this study had mounted
a T cell response against antigens expressed by their
tumors. We have begun to explore the immune infiltrate
and transcriptome of HNSCC and are looking for correla-
tions between the immunoprofile, gene expression,
detection of tumor-specific TIL and outcome in patients
with HNSCC.
Conclusions
We hypothesize that results of these studies could be used
to stratify patients for clinical trials and ultimately tailor
combination immunotherapy for patients with this disease.
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